

Advances in the Management of Pancreatic Cancer: From Bench to Bedside



REFERENCES

1. AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA) in Metastatic Pancreatic Cancer. <https://news.abbvie.com/news/abbvie-provides-update-on-phase-3-study-ibrutinib-imbruvica-in-metastatic-pancreatic-cancer.htm>
2. AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer: <https://news.abbvie.com/news/abbvie-provides-update-on-phase-3-study-ibrutinib-imbruvica-in-metastatic-pancreatic-cancer.htm>
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol*. 1997;15:2403-2413. doi:10.1200/JCO.1997.15.6.2403
4. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. *Ann Surg Oncol*. 2009;16:1727-1733. doi:10.1245/s10434-009-0408-6
5. Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell*. 2017;32:185-203. doi:10.1016/j.ccell.2017.07.007
6. ClinicalTrials.gov Identifier: NCT02436668.
7. Connor AA, Denroche RE, Jang GH, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. *JAMA Oncol*. 2017;3:774-783.
8. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med*. 2011;364:1817-1825. doi:10.1056/NEJMoa1011923
9. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med*. 2018;379:2395-2406. doi: 10.1056/NEJMoa1809775
10. Conroy T, Hammel P, Hebbar M, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinomas. *J Clin Oncol*. 2018;36:LBA4001. doi:10.1200/JCO.2018.36.18_suppl.LBA4001
11. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. *Gut*. 2007;56:1134-1152. doi:10.1136/gut.2006.103333
12. Gill S, et al. PANCREOX: A randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. *J Clin Oncol*. 2016;34:3914-3920. doi:10.1200/JCO.2016.68.5776
13. Golan T, Kindler H. NCT02184195. Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy.
14. Gourgou-Bourgade S, Bascoul-Mollevis C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. *J Clin Oncol*. 2013;31: 23-29. doi:10.1200/JCO.2012.44.4869
15. Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. *Cancer Discov*. 2016;6:270-285.
16. Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. *J Clin Oncol*. 2018;36:359-366. doi:10.1200/JCO.2017.74.9564
17. Hingorani SR, Bullock AJ, Seery TE, et al. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). *J Clin Oncol*. 2017;35:Abstr.4008. doi:10.1200/JCO.2017.35.15_suppl.4008

18. Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations. *Clin Cancer Res.* 2018;24:1326-1336. doi:10.1158/1078-0432.CCR-17-3099
19. Hu ZI, Shia J, Stadler ZK, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: Challenges and recommendations. *Clin Cancer Res.* 2018;24:1326-1336. doi:10.1158/1078-0432.CCR-17-3099
20. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. *Pancreatology.* 2018;18:2-11. doi:10.1016/j.pan.2017.11.011
21. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut.* 2013;62:112-120. doi:10.1136/gutjnl-2012-302529
22. Katz MH, Mortenson MM, Wang H, et al. Diagnosis and management of neoplasms of the pancreas: An evidence-based approach. *J Am Coll Surg.* 2008;207:106-120. doi:10.1016/j.jamcollsurg.2007.12.048
23. Krantz BA, O'Reilly EM. Biomarker-based therapy in pancreatic ductal adenocarcinoma: An emerging reality? *Clin Cancer Res.* 2018;24:2241-2250. doi:10.1158/1078-0432.ccr-16-3169
24. Krantz BA, Yu KH, O'Reilly EM. Pancreas adenocarcinoma: Novel therapeutics. *Chin Clin Oncol.* 2017;6:30. doi:10.21037/cco.2017.06.14
25. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* 2017;357:409-413. doi:10.1126/science.aan6733
26. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015;372:2509-2520. doi:10.1056/NEJMoa1500596
27. Lowery MA, Wong W, Jordan EJ, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. *J Natl Cancer Inst.* 2018;110:1067-1074. doi:10.1093/jnci/djy024
28. Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. *JAMA.* 2017;318:825-835. doi:10.1001/jama.2017.11137
29. Massó-Vallés D, Jauset T, Serrano E, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. *Cancer Res.* 2015;75:1675-1681.
30. NCCN Guidelines. Version 1.2019.
31. NCT03214250. Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma.
32. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. *Nat Rev Gastroenterol Hepatol.* 2018;15:333-348. doi:10.1038/s41575-018-0005-x
33. Neoptolemos JP, Palmer D, Ghaneh P, et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. *J Clin Oncol.* 2016;34:LBA4006. doi:10.1200/JCO.2016.34.18_suppl.LBA4006
34. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet.* 2017;389:1011-1024. doi:10.1016/S0140-6736(16)32409-6
35. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med.* 2004;350:1200-1210. doi:10.1056/NEJMoa032295
36. Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. *Bioinformatics.* 2014;30:1015-1016. doi:10.1093/bioinformatics/btt755
37. O'Reilly EM, et al. Gastrointestinal Cancers Symposium, 2018. NCT02558894. Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma.
38. O'Reilly EM. Unpublished data.
39. O'Reilly EM. Unpublished data. MSKCC.
40. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 RANDOMIZED TRIAL. *JAMA.* 2013;310:1473-1481. doi:10.1001/jama.2013.279201
41. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. *JAMA.* 2007;297:267-277. doi:10.1001/jama.297.3.267

42. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. *J Clin Oncol*. 2014;32:2423-2429. doi:10.1200/JCO.2013.53.6995
43. O'Reilly EM, Kelsen D. NCT01585805. Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer.
44. O'Reilly EM, Lee JW, Lowery MA, et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. *Cancer*. 2018;124:1374-1382. doi:10.1002/cncr.31218
45. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer Cell*. 2012;21:418-429. doi:10.1016/j.ccr.2012.01.007
46. Rahib L, Smith BD, Alzenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res*. 2014;74:2913-2921. doi:10.1158/0008-5472.CAN-14-0155
47. Ramanathan RK, et al. Gastrointestinal Cancers Symposium, 2018.
48. Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a ransomised, open-label, phase 2-3 trial. *Lancet Gastroenterol Hepatol*. 2018;3:413-423. doi:10.1016/S2368-1253(18)30081-5
49. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. *J Immunother*. 2010;33:828-833. doi:10.1097/CJI.0b013e3181eec14c
50. SEER Cancer Statistics Review.
51. Segal NH, Antonia SJ, Brahmer JR, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. *J Clin Oncol*. 2014;32:Abstr. 3002. doi:10.1200/jco.2014.32.15_suppl.3002
52. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69:7-34. doi:10.3322/caac.21551
53. van Tienhoven G, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. *J Clin Oncol*. 2018;36:LBA4002. doi: 10.1200/JCO.2018.36.18_suppl.LBA4002
54. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med*. 2013;369:1691-1703. doi:10.1056/NEJMoa1304369
55. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. *Lancet*. 2016;387:545-557. doi:10.1016/S0140-6736(15)00986-1